Biodexa Pharmaceuticals Plc
BDRX · XNASCIK 1643918fmd_06ZSG715H3YSVSM7QPZN11BB5NManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 16 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 2 | 1 | 0 | 1 | 1 | 0 | – | – |
| Cost of revenue | 1 | 1 | – | – | – | – | – | – | – | – |
| Gross profit | 6 | 7 | – | – | – | – | – | – | – | – |
| Research and development | 8 | 8 | 9 | 8 | 6 | 5 | 5 | 4 | 5 | 4 |
| Selling, general and administrative | 18 | 4 | – | 4 | 5 | – | – | – | – | – |
| Operating income | (10) | (13) | (12) | (11) | (23) | (7) | (9) | (8) | (9) | (9) |
| Interest expense | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (8) | (13) | (12) | (11) | (23) | (6) | (8) | (7) | (6) | (6) |
| Income tax expense | (2) | (1) | (2) | 2 | (1) | (1) | (1) | (0) | (0) | (0) |
| Net income from continuing operations | (6) | (12) | (10) | (9) | (22) | (5) | (8) | (7) | (6) | (6) |
| Net income | (20) | (16) | (15) | (10) | (22) | (5) | (8) | (7) | (6) | (6) |